Polysaccharide Antibody Response Study

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Specific Polysaccharide Antibody Deficiency
Interventions
BIOLOGICAL

Pneumovax 23 (Sanofi Pasteur MSD)

Intramuscular injection of Pneumovax 23 vaccine (0.5 ml).

BIOLOGICAL

Typhim Vi (Sanofi Pasteur MSD)

Intramuscular injection of Typhim Vi vaccine (0.5 ml).

Trial Locations (1)

3000

UZ Leuven, Leuven

All Listed Sponsors
collaborator

KU Leuven

OTHER

lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT02429531 - Polysaccharide Antibody Response Study | Biotech Hunter | Biotech Hunter